On Target receives $5.2M in Funding for Cancer Fluorescence Compound
On Target Laboratories LLC, whose fluorescent imaging technology enables surgeons to identify and remove more cancerous tissue than previously possible, said it has received $5.2 million in private funding as it prepares to enter phase 3 clinical trials in ovarian cancer and phase 2 clinical trials in lung cancer.
OTL38, a product of On Target Laboratories LLC, binds with diseased tissue present in several cancers, causing the tissue to fluoresce during cancer surgery. Courtesy of PRNewsFoto/On Target Laboratories LLC.
On Target's lead molecule OTL38 is a patented small molecule designed to target and illuminate greater than 40 percent of all solid tumors. It has been administered to more than 200 patients in investigator-sponsored trials in renal, endometrial, lung and pituitary cancers, and a phase 2 in ovarian cancer.
The company said its researchers have recently identified additional molecules that could target the majority of all remaining cancers and that its next molecule, OTL78, is being manufactured in preparation for clinical trials to begin early next year.
On Target Laboratories develops small molecules that, when conjugated with fluorescent dyes, target and illuminate specific cancerous cells and other diseased tissue. These conjugates can be used by doctors, worldwide to diagnose and treat a range of diseases from cancer to inflammation-related disorders.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024